Mental health care utilization among men with castration‐resistant prostate cancer receiving abiraterone or enzalutamide

BACKGROUND: Abiraterone and enzalutamide are castration‐resistant prostate cancer (CRPC) therapies with potentially distinct associations with mental health symptoms given their differing antiandrogen targets. METHODS: We used national Veterans Health Administration data to identify patients with CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsao, Phoebe A., Burns, Jennifer, Kumbier, Kyle, Sparks, Jordan B., Entenman, Shami, Bloor, Lindsey E., Bohnert, Amy S. B., Skolarus, Ted A., Caram, Megan E. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469813/
https://www.ncbi.nlm.nih.gov/pubmed/37325888
http://dx.doi.org/10.1002/cam4.6237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469813/
https://www.ncbi.nlm.nih.gov/pubmed/37325888
http://dx.doi.org/10.1002/cam4.6237

Ejemplares similares